Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2581124 | 0.85 | MEN1 (0.37) | RIPK1P2RX7MEN1KMT2A | |
| SCHEMBL2581567 | 0.81 | P2RX7 (0.41) | RIPK1P2RX7MEN1KMT2A | |
| SCHEMBL2588037 | 0.80 | P2RX7 (0.34) | RIPK1P2RX7KDM1A | |
| SCHEMBL4513860 | 0.78 | P2RX7 (0.32) | P2RX7 | |
| SCHEMBL4513488 | 0.78 | P2RX7 (0.32) | P2RX7 | |
| SCHEMBL3623238 | 0.78 | P2RX7 (0.32) | P2RX7 | |
| SCHEMBL3623239 | 0.78 | P2RX7 (0.32) | P2RX7 | |
| SCHEMBL4500998 | 0.77 | TSHR (0.41) | RIPK1P2RX7MEN1KMT2A | |
| SCHEMBL4501000 | 0.77 | TSHR (0.41) | RIPK1P2RX7MEN1KMT2A | |
| SCHEMBL4521177 | 0.75 | P2RX7 (0.39) | RIPK1P2RX7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953158-B1 | BICYCLIC CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-8048878-B2 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | RIPK1 4491/4885P2RX7 1836/4885KDM1A 1703/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | RIPK1 4491/4885P2RX7 1836/4885KDM1A 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.